Core Opinion - The audit report for BrightGene (Suzhou) Co., Ltd. indicates that the financial statements for the year ending December 31, 2024, fairly represent the company's financial position and results of operations in accordance with accounting standards [2][3]. Financial Statements - The audit covered the consolidated and parent company balance sheets, income statements, cash flow statements, and changes in equity for the year 2024 [2]. - The financial statements are prepared based on the going concern assumption, indicating that the company is expected to continue its operations for the foreseeable future [17]. Key Audit Matters - Revenue recognition is identified as a key audit matter due to its significant impact on the consolidated financial statements and the complexity of the conditions for revenue recognition [3][4]. - The company recognizes sales revenue from domestic and export sales upon delivery and receipt of payment, ensuring that economic benefits are likely to flow [3]. - Technical income is recognized upon completion of contractual obligations, with specific criteria for contracts that include refund clauses [3][4]. - The assessment of accounts receivable and the adequacy of the allowance for bad debts are also considered key audit matters due to the significant amounts involved and the complexity of management's judgments [4][5]. Management Responsibilities - Management is responsible for preparing financial statements that fairly present the company's financial position and for maintaining effective internal controls to prevent material misstatements [6]. - The governance layer oversees the financial reporting process, ensuring compliance with relevant accounting standards [6]. Auditor Responsibilities - The auditor's goal is to obtain reasonable assurance that the financial statements are free from material misstatement, whether due to fraud or error [6][7]. - The auditor evaluates the appropriateness of accounting policies and estimates made by management, as well as the overall presentation of the financial statements [7][8]. Company Overview - BrightGene (Suzhou) Co., Ltd. was established on August 20, 2015, and has undergone several changes in its capital structure and ownership since its inception [9][10]. - The company specializes in the research and development of pharmaceutical products, including APIs and intermediates, and has a registered capital of approximately 61,000 USD [9][10].

Core Viewpoint - BrightGene Bio-Medical Technology Co., Ltd. is issuing shares to specific investors to enhance its capital structure and support its growth strategy in the pharmaceutical industry. Group 1: Company Overview - Company Name: BrightGene Bio-Medical Technology Co., Ltd. [1] - Registered Capital: 422.465 million yuan [1] - Stock Code: 688166 [1] - Listing Location: Shanghai Stock Exchange Sci-Tech Innovation Board [1] - Established: October 26, 2001 [3] - Listing Date: November 8, 2019 [3] - Main Business: The company focuses on innovative pharmaceuticals, emphasizing research and development in generic drugs, complex formulations, and original new drugs [3][4]. Group 2: Business Model and Product Portfolio - The company operates a full industry chain from raw materials to high-difficulty intermediates and specialty APIs, extending into the formulation sector [5]. - Key therapeutic areas include antiviral, antifungal, immunosuppressive, respiratory, oncology, and metabolic diseases [4]. - Core products in the antiviral field include Entecavir and Oseltamivir, while in the antifungal field, key products include Caspofungin and Micafungin Sodium [4]. Group 3: Financial Data - Total Assets as of March 31, 2025: 528,527.33 million yuan [8] - Total Liabilities as of March 31, 2025: 266,925.64 million yuan [8] - Total Equity as of March 31, 2025: 261,601.69 million yuan [8] - Revenue for Q1 2025: 24,895.98 million yuan [9] - Net Profit for 2024: 14,126.33 million yuan [9] Group 4: Share Issuance Details - Type of Shares: Domestic listed ordinary shares (A shares) with a par value of 1.00 yuan [28]. - Issuance Price: 22.36 yuan per share [25]. - Total Amount to be Raised: Up to 500 million yuan [28]. - Use of Proceeds: To supplement working capital and repay bank loans [28].

Core Viewpoint - The legal opinion letter from Beijing Jingtian & Gongcheng Law Firm confirms that BrightGene Bio-Medical Technology (Suzhou) Co., Ltd. is authorized to issue A-shares to specific investors in 2024, ensuring compliance with relevant laws and regulations [3][8][10]. Group 1: Issuance and Approval - The board of directors has approved various proposals related to the issuance of A-shares, including feasibility analysis and usage of raised funds [6][7]. - The shareholders' meeting has authorized the board to handle matters related to the issuance of A-shares, extending the validity of related resolutions until May 20, 2026 [6][7]. - The issuance of A-shares is subject to approval from the Shanghai Stock Exchange and the China Securities Regulatory Commission [8]. Group 2: Company Qualifications - BrightGene is a legally established and effectively existing public company, possessing the qualifications to implement the issuance and listing of A-shares [8][10]. - The issuance of A-shares complies with the relevant conditions set forth in the Company Law and Securities Law, ensuring equal rights for all shares issued [8][10]. Group 3: Independence and Operations - The company operates independently from its controlling shareholders and actual controllers, with no reliance on them for business operations [12][14]. - BrightGene has established independent systems for research, procurement, production, and sales, ensuring operational autonomy [12][14]. Group 4: Shareholder Structure - As of June 30, 2025, the major shareholders include Mr. Yuan Jiandong and Ms. Zhong Weifang, who collectively control 38.53% of the company [15]. - The shareholding structure is legally valid, with no disputes regarding ownership [15][16]. Group 5: Financial and Asset Integrity - The company maintains an independent financial accounting system and has established strict financial management practices [13][14]. - BrightGene possesses complete ownership of its assets, including land, buildings, and intellectual property, with no disputes or potential conflicts [20][21].

Core Viewpoint - Minsheng Securities is acting as the sponsor for the specific stock issuance of Borui Biopharmaceuticals (Suzhou) Co., Ltd., ensuring compliance with relevant laws and regulations [1][2]. Group 1: Basic Information about the Issuer - The issuer, Borui Biopharmaceuticals (Suzhou) Co., Ltd., is primarily engaged in the research and production of high-tech pharmaceutical intermediates, active pharmaceutical ingredients, and formulation products [5]. - The company was established on October 26, 2001, with a registered capital of 422,465,050 yuan [5]. - The company went public on November 8, 2019, and its stock code is 688166 [5]. Group 2: Share Structure and Major Shareholders - As of June 30, 2025, the total share capital of the company is 422,768,244 shares, all of which are unrestricted shares [6]. - The top ten shareholders hold a combined 48.25% of the shares, with the largest shareholder being Suzhou Borui Xinwen Management Consulting Partnership [6]. Group 3: Financial Performance - As of March 31, 2025, the total assets of the company amounted to 528,527.33 million yuan, with total liabilities of 266,925.64 million yuan [7]. - The company reported a net profit of -465.68 million yuan for the first quarter of 2025, compared to a net profit of 14,126.33 million yuan for the entire year of 2024 [7]. - The operating income for the first quarter of 2025 was 24,895.98 million yuan, while the total revenue for 2024 was 128,255.16 million yuan [7]. Group 4: Issuance Details - The company plans to issue shares to specific investors at an initial price of 22.56 yuan per share, which is compliant with the pricing regulations [20]. - The issuance is subject to approval from the Shanghai Stock Exchange and the China Securities Regulatory Commission [20]. Group 5: Compliance and Regulatory Aspects - The sponsor has conducted due diligence and confirmed that the issuer meets the necessary legal and regulatory requirements for the stock issuance [14][15]. - The issuance does not involve any prohibited circumstances as outlined in the Securities Law [21]. Group 6: Decision-Making Process - The board of directors approved the issuance plan on May 6, 2024, and subsequent meetings have reaffirmed and adjusted the plan as necessary [16][19]. - The shareholders' meeting on May 20, 2024, also approved the issuance plan and authorized the board to handle related matters [19].

博瑞生物医药（苏州）股份有限公司（以下简称"公司"）于 2025 年 8 月 药（苏州）股份有限公司科创板上市公司发行证券申请的通知》（上证科审（再 融资）[2025]92 号）。上交所依据相关规定对公司报送的科创板上市公司发行证 券的募集说明书及相关申请文件进行了核对，认为该项申请文件齐备，符合法定 形式，决定予以受理并依法进行审核。 公司本次向特定对象发行 A 股股票事项尚需通过上交所审核，并获得中国 证券监督管理委员会（以下简称"中国证监会"）作出同意注册的决定后方可实 施。最终能否通过上交所审核，并获得中国证监会同意注册的决定及其时间尚存 在不确定性。公司将根据该事项的进展情况及时履行信息披露义务，敬请广大投 资者注意投资风险。 特此公告。 证券代码：688166 证券简称：博瑞医药 公告编号：2025-054 博瑞生物医药（苏州）股份有限公司 关于 2024 年度向特定对象发行 A 股股票申请获得上 海证券交易所受理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 博瑞生物医药（苏州）股份有限公司董事会 ...

| 成交量（万 | 成交金额（万 | | 成交价格 | 相对当日收盘折溢价 | 买方营 | 卖方营业部 | | --- | --- | --- | --- | --- | --- | --- | | 股） | | 元） | （元） | （%） | 业部 | | | 16.00 | 1677.60 | | 104.85 | -9.99 | 机构专 | 国投证券股份有限公司江 | | | | | | | 用 | 苏分公司 | | 10.00 | 1048.50 | | 104.85 | -9.99 | 机构专 | 国投证券股份有限公司江 | | | | | | | 用 | 苏分公司 | 博瑞医药8月11日大宗交易平台共发生2笔成交，合计成交量26.00万股，成交金额2726.10万元。成交价 格均为104.85元，相对今日收盘价折价9.99%。从参与大宗交易营业部来看，机构专用席位共出现在2笔 成交的买方或卖方营业部中，合计成交金额为2726.10万元，净买入2726.10万元。 （文章来源：证券时报网） 进一步统计，近3个月内该股累计发生18笔大宗交易，合计成交金额为1.84亿元。 证券时报·数据宝统计显示，博 ...

证券日报网讯 8月11日晚间，博瑞医药发布公告称，公司于2025年8月8日收到上海证券交易所（简 称"上交所"）出具的《关于受理博瑞生物医药（苏州）股份有限公司科创板上市公司发行证券申请的通 知》（上证科审（再融资）[2025]92号）。上交所依据相关规定对公司报送的科创板上市公司发行证券 的募集说明书及相关申请文件进行了核对，认为该项申请文件齐备，符合法定形式，决定予以受理并依 法进行审核。公司本次向特定对象发行A股股票事项尚需通过上交所审核，并获得中国证券监督管理委 员会（简称"中国证监会"）作出同意注册的决定后方可实施。最终能否通过上交所审核，并获得中国证 监会同意注册的决定及其时间尚存在不确定性。 （文章来源：证券日报） ...

| 交易日期 | 证券简称 | 证券代码 | 成交价(元) | 成交金额(万元) 成交量( * ) 买入营业部 | | | 卖出营业部 | | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-08-11 | 博瑞医药 | 688166 | 104.85 | 1677.6 16 | 机构专用 | 国投证券股份有限 公司江苏分公司 | | | 2025-08-11 | 博瑞医药 | 688166 | 104.85 | 1048.5 10 | 机构专用 | 国投证券股份有限 公司江苏分公司 | | 8月11日，博瑞医药大宗交易成交26万股，成交额2726.1万元，占当日总成交额的2.31%，成交价104.85元，较市场收盘价116.49元折价9.99%。 ...

沪深两市全天主力资金净流入100.20亿元，其中，科创板主力资金净流出20.87亿元，主力资金净流入的 有243只股，主力资金净流出的有344只股。 证券时报·数据宝统计显示，今日科创板个股上涨的有499只，涨停的有赛诺医疗、莱尔科技等2只，下 跌的有85只。 资金流向方面，今日主力资金净流入的科创板股共有243只，其中，10只个股主力资金净流入超5000万 元，东芯股份主力资金净流入1.86亿元，净流入资金居首；寒武纪、云从科技紧随其后，全天净流入资 金分别为1.38亿元、9916.17万元。主力资金净流出的有344只，净流出资金最多的是中芯国际，该股今 日上涨0.35%，全天主力资金净流出2.60亿元，其次是海光信息、芯原股份，主力资金净流出分别为 2.30亿元、2.22亿元。 从主力资金连续性进行观察，共有36只个股主力资金连续3个交易日以上持续净流入，连续流入天数最 多的是龙软科技，该股已连续8个交易日净流入；连续净流入天数较多的还有博瑞医药、鼎阳科技等， 主力资金分别连续流入7天、7天。主力资金连续流出的个股有140只，连续流出天数最多的是亿华通， 该股已连续18个交易日净流出；连续净流出天数较多的 ...

证券代码：688166 证券简称：博瑞医药 公告编号：2025-054 博瑞生物医药（苏州）股份有限公司 关于 2024 年度向特定对象发行 A 股股票申请获得上 海证券交易所受理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 特此公告。 博瑞生物医药（苏州）股份有限公司（以下简称"公司"）于 2025 年 8 月 8 日收到上海证券交易所（以下简称"上交所"）出具的《关于受理博瑞生物医 药（苏州）股份有限公司科创板上市公司发行证券申请的通知》（上证科审（再 融资）[2025]92 号）。上交所依据相关规定对公司报送的科创板上市公司发行证 券的募集说明书及相关申请文件进行了核对，认为该项申请文件齐备，符合法定 形式，决定予以受理并依法进行审核。 公司本次向特定对象发行 A 股股票事项尚需通过上交所审核，并获得中国 证券监督管理委员会（以下简称"中国证监会"）作出同意注册的决定后方可实 施。最终能否通过上交所审核，并获得中国证监会同意注册的决定及其时间尚存 在不确定性。公司将根据该事项的进展情况及时履行信息披露义务， ...